ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: strong revenue growth and optimistic guidance, particularly for NUPLAZID, contrast with increased R&D and SG&A expenses. The absence of a share repurchase program and unresolved regulatory and competitive challenges add uncertainty. The Q&A section reveals confidence in future pricing and product success, but also highlights risks in regulatory approval and market competition. Given the market cap of approximately $2.7 billion, the overall sentiment suggests a neutral stock price movement in the near term.
Key Financial Performance
Total Revenue $244.3 million, up 19% year-over-year.
DAYBUE Net Product Sales $84.6 million, up 11% year-over-year, driven by an all-time high in unique patients receiving shipments.
NUPLAZID Net Product Sales $159.7 million, up 23% year-over-year, with 6% attributable to volume and a one-time change in gross to net due to Medicare Part D redesign.
R&D Expenses $78.3 million, up from $59.7 million year-over-year, due to increased spending on clinical stage programs.
SG&A Expenses $126.4 million, up from $108 million year-over-year, primarily driven by the continuation of the NUPLAZID consumer activation campaign and higher commercial operation expenses.
Cash Balance $681.6 million as of March 31.
Cash Flow from Operating Activities Positive in the quarter, but cash declined sequentially due to $98.8 million in payments made to Neuren.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DAYBUE Sales: Generated $84.6 million in DAYBUE sales in Q1 2025, up 11% from a year ago.
NUPLAZID Sales: Reported $159.7 million in revenue for NUPLAZID in Q1 2025, up 23% from the prior year.
International Expansion: Plans for a strong launch of DAYBUE outside the U.S. pending EMA approval in Q1 2026.
Distribution Agreements: Entered into agreements for named patient access in Latin America, Middle East, Asia Pacific, and other regions.
Patient Engagement: Achieved an all-time record of 954 unique patients receiving DAYBUE shipments.
Field Force Expansion: Completed planned hires for the expanded customer model to drive DAYBUE sales growth.
R&D Pipeline: Accelerated timeline for COMPASS PWS Phase 3 study results expected by Q4 2025.
Consumer Activation Campaigns: Continued efforts to increase awareness and diagnosis of Parkinson’s disease psychosis.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The marketing authorization application for trofinetide in the EU is under review, with anticipated approval in Q1 2026. There are ongoing engagements with the PMDA in Japan, which are productive, and orphan drug designation has been received.
Supply Chain Challenges: There is uncertainty around potential tariffs affecting both NUPLAZID and DAYBUE, although the company has substantial inventory on hand to meet anticipated demand.
Economic Factors: The impact of the Medicare Part D redesign has affected net pricing for DAYBUE and NUPLAZID, with adjustments leading to fluctuations in gross to net pricing.
Competitive Pressures: The company faces competition in the Parkinson’s disease psychosis market, with efforts to increase awareness and diagnosis among patients to ensure NUPLAZID is recognized as a first-line therapy.
R&D Challenges: ACADIA has concluded that there is no viable path forward for certain programs, specifically the Rett and Undisclosed Programs, leading to a winding down of efforts.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
DAYBUE Sales Growth: First quarter sales were $84.6 million, up 11% from a year ago, with a record number of unique patients served.
NUPLAZID Sales Growth: NUPLAZID achieved first quarter sales of $159.7 million, representing 23% revenue growth year over year.
Expansion Plans: Plans to expand DAYBUE's market presence outside the U.S. with a focus on Europe, anticipating EMA approval in Q1 2026.
R&D Pipeline Updates: COMPASS PWS Phase 3 study results expected by Q4 2025, with potential regulatory submission in Q1 2026.
Consumer Activation Campaigns: Continued focus on consumer engagement to drive awareness and treatment of Parkinson’s disease psychosis.
2025 Revenue Guidance: Reiterating full year 2025 financial guidance with total revenue expected to grow.
R&D Expense Guidance: Expecting R&D expenses to be between $330 million to $350 million, up from prior guidance of $310 million to $330 million.
Inventory Management: Substantial inventory on hand for both NUPLAZID and DAYBUE, sufficient to meet demand into the mid to late 2030s.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What does good 101 data look like? And can you discuss how that may relate to your last discussions with FDA on the filing strategy?
A:We are ahead of schedule with respect to 101 and expect data by the end of the year. A good outcome would be a statistically significant result demonstrating a clinically meaningful impact on hyperphagia.
Q:How should we be thinking about modeling a European price for DAYBUE?
A:We are confident in getting a strong EU price that reflects the value we bring to the Rett community. We will continue to update as discussions progress.
Q:What is the right way for us to be thinking about what we are likely to see sequentially from 1Q to 2Q from a growth perspective?
A:DAYBUE is expected to see continued growth due to an expanded customer model and increased patient ads. NUPLAZID is also seeing positive momentum.
Q:What makes you confident that low-dose Carbetocin can generate positive data and be accepted by the FDA?
A:We have mechanistic reasons to believe in Carbetocin's relevance in Prader-Willi and see signs of internal consistency in the 3.2-mg dose dataset.
Q:Are there any phenotypic behaviors or patient subsets that are more likely to respond to treatment in the Phase 3 COMPASS trial?
A:We haven't identified patient subsets that are more or less likely to respond to Carbetocin based on the current dataset.
Q:Can you provide some color on the utilization rate or compliance in the quarter for DAYBUE?
A:Compliance was in the high 60s, slightly down from the previous quarter, but we believe this is due to patients becoming more confident in their titration strategies.
Q:What do you see as the biggest risk to the approval process for trofinetide in the EU?
A:We are confident in our EMA timeline and have no communication suggesting we are not proceeding as expected.
Q:What unique aspects of your commercial engine do you believe you’ll be able to leverage to rise above competitors in the PWS market?
A:We have a strong team with experience in rare spaces and strong associations with the Prader-Willi community, which will help us compete effectively.
Q:What pushes and pulls do you expect could move the gross net one side or another of the guide for NUPLAZID?
A:It depends on patient mix and any pricing actions we may take, which can influence quarterly fluctuations.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific effect size and powering of the study for Carbetocin, stating that they have not identified patient subsets that are more or less likely to respond to treatment in the COMPASS trial. Additionally, there was a lack of clarity on the specific dynamics of pricing and reimbursement in Europe for DAYBUE, as well as the potential impact of most favored nation drug pricing developments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACP indication
Adams
America
Bank
Body Dementia
COMPASS PWS
Carbetocin
DAYBUE year
Dementia Psychosis
EVP
HCP
Lewy Body
Medicare redesign
PWS Phase
Phase study
Phase trial
Pimavanserin
Prader Willi
RD
change net
consumer
debut
expansion
hallucination delusion
inventory
line result
mid
momentum
number patient
oxytocin
patient line
patient shipment
review
shipment fact
syndrome patient
timeline
track Phase
ACAD Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript
Unknown5-8
The earnings call summary presents a mixed picture: strong revenue growth and optimistic guidance, particularly for NUPLAZID, contrast with increased R&D and SG&A expenses. The absence of a share repurchase program and unresolved regulatory and competitive challenges add uncertainty. The Q&A section reveals confidence in future pricing and product success, but also highlights risks in regulatory approval and market competition. Given the market cap of approximately $2.7 billion, the overall sentiment suggests a neutral stock price movement in the near term.
Earnings call transcript: Acadia Pharmaceuticals beats Q1 2025 forecasts
Unknown5-7
The earnings call summary presents a mixed picture. Financial performance shows positive revenue growth but increased expenses. The Q&A highlights potential risks, such as regulatory and competitive pressures, and management's lack of clarity on certain issues. Despite the optimistic guidance and strong revenue growth, the absence of shareholder return plans and increased R&D expenses temper enthusiasm. Given the market cap, the stock is likely to remain stable, resulting in a neutral prediction.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
Positive11-7
The earnings call summary indicates strong financial performance with significant year-over-year sales growth for both DAYBUE and NUPLAZID. The company is in a strong financial position with a substantial cash balance and no debt, which supports future growth and potential shareholder returns. Although there is a lowered guidance for DAYBUE, the increased guidance for NUPLAZID and the sale of a priority review voucher enhance the positive sentiment. The Q&A section reveals some uncertainties, but overall, the financial metrics and strategic initiatives suggest a positive stock price movement.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript
Positive8-7
The earnings call reveals strong financial performance with a 46% increase in net sales, driven by DAYBUE and NUPLAZID. Despite lowered guidance for DAYBUE, optimistic guidance and strategic initiatives like DTC campaigns and pipeline advancements are highlighted. The Q&A section indicates confidence in future growth and addresses operational strategies. The lack of share buybacks or dividends is offset by robust cash flow. Considering the market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
ACAD Slides
ACAD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
